Sean Callahan, MD
Otolaryngology · Fort Worth, TXNPI 1366641581
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 32.8% of the total. 2025 is the largest year on record at $1,008, 2.7 times the $375 reported in 2019.
Across 69 payments — averaging $42.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$963
- Acclarent, Inc$507
- Stryker$382
- Integra Lifesciences Corporation$207
- Medtronic$182
- Optinose US, Inc.$158
- plus $535 from 11 others
Across 37 payments — averaging $2749.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$102K
What the payments were for
- Food & beverage$2,934100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 24 | $963 |
| Acclarent, Inc | 7 | $507 |
| Stryker | 5 | $382 |
| Integra Lifesciences Corporation | 4 | $207 |
| Medtronic(2 entities) | 5 | $182 |
| Optinose US, Inc. | 3 | $158 |
| Aerin Medical Inc. | 4 | $139 |
| Smith+Nephew | 4 | $86 |
| Galderma Laboratories, L.p. | 1 | $75 |
| GSK | 4 | $68 |
| Sanofi | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Olympus America Inc. | 2 | $32 |
| Novartis | 1 | $20 |
| Merck | 1 | $18 |
| Neurent Medical Limited | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$413
- RELIEVA SPINPLUS Balloon Sinuplasty System$204
- SCOPIS ENT$174
- TruDi Nav Cable$145
- SPIROX - LATERA$139
- Xhance$124
- Acclarent Aera$121
- Inspira Air$121
- RELIEVA SPINPLUS NAV$121
- TruDi Probe$121
- StealthStation$108
How this compares
$2,934 in reported general payments places this provider in the 60th percentile of 729 otolaryngology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 76 | $2,833 |
| Fluticasone Propionate | 165 | $2,442 |
| Epinephrine | 13 | $1,853 |
| Azelastine Hcl | 36 | $987 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 61 | $551 |
| CefuroximeCefuroxime Axetil | 27 | $547 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 31 | $515 |
| Omeprazole | 32 | $447 |
| Montelukast Sodium | 37 | $390 |
| Mupirocin | 36 | $310 |
| Prednisone | 54 | $252 |
| Ofloxacin | 12 | $226 |
| Cephalexin | 18 | $195 |
| Methylprednisolone | 23 | $190 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAEpinephrine | $15 | $1,85313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 729 otolaryngology providers in Texas.
Other otolaryngology in Fort Worth
- Marc DeanFort Worth$486K
- Jeremy WatkinsFort Worth$17K
- Jesse SmithFort Worth$16K
- Amber LuongHouston$426K
- Arjuna KuperanHouston$348K
- Ronald KuppersmithCollege Station$325K
- Ron KarniHouston$317K
- Philip ChenSan Antonio$305K
- Jordan RihaniSouthlake$280K
- Keith MathenyFrisco$269K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.